The Board of Directors of SynAct Pharma AB (publ) (“SynAct” or the "Company") has, on this date, pursuant to the authorization granted by the extraordinary general meeting held on 27 November 2025, resolved on the repurchase of own shares on Nasdaq Stockholm for the purpose of distributing capital to shareholders and adjusting the Company's capital structure.

The repurchases shall be carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (MAR) and the European Commission’s Delegated Regulation (EU) No 2016/1052 (the Safe Harbour Regulation). The repurchase of shares will be executed by Mangold Fondkommission (”Mangold”) which, pursuant to the trading order issued by SynAct to Mangold, shall make its trading decisions independently of SynAct with respect to the timing of the acquisitions of SynAct shares. Reports on repurchases shall be made in accordance with applicable rules and regulations.

The purpose of the repurchases is to distribute excess liquidity and thereby adjust the Company's capital structure through a reduction of the share capital. Accordingly, the Board of Directors intends to propose to the Annual General Meeting 2026 that the repurchased shares shall be redeemed. The reduction of the share capital is intended to be offset by a corresponding bonus issue in order to restore the share capital to its previous amount.

The repurchases shall be subject to the following terms and conditions resolved upon by the Board of Directors:

• The repurchases shall be executed on Nasdaq Stockholm in accordance with its Nordic Main Market Rulebook for Issuers of Shares and in accordance with MAR and the Safe Harbour Regulation.
• The shares shall be acquired at a price per share within the price interval registered on Nasdaq Stockholm at any given time, being the interval between the highest buying price and the lowest selling price as continuously published by Nasdaq Stockholm.
• The maximum number of own shares that may be repurchased shall be limited such that the Company's holding of own shares at any given time does not exceed ten (10) per cent of the total number of shares in the Company. The maximum aggregate acquisition amount is SEK 5 million.
• The repurchases may be executed on one or more occasions and shall commence no earlier than 12 January 2026 and shall be completed no later than 28 February 2026.
• Payment for the shares shall be made in cash.

As of the date hereof, the total number of shares and votes in the Company amounts to 53,330,243. The Company holds no own shares as of the date of this resolution.

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

This information is information that SynAct Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-09 19:16 CET.

Attachments
The Board of Directors of SynAct Pharma AB (publ) has resolved on the repurchase of own shares

Läs mer på MFN